CytoKi Pharma
CytoKi Pharma is a pre-clinical biotechnology company with focus on serious diseases caused by epithelial injury with a high medical need.
Cytoki’s lead program is based on an engineered long-acting IL-22 protein. Founded in 2019, CytoKi received seed financing from BioCapital in July 2019. The company has strong focus on progressing the lead program to clinical testing.
